{"product_id":"lly-marketing-mix","title":"Eli Lilly and Company (LLY): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made late-2025 Marketing Mix Analysis gives you a clear, research-based view of Eli Lilly and Company’s business across \u003cstrong\u003eobesity\u003c\/strong\u003e, \u003cstrong\u003ediabetes\u003c\/strong\u003e, \u003cstrong\u003eoncology\u003c\/strong\u003e, and \u003cstrong\u003eneuroscience\u003c\/strong\u003e, showing how \u003cstrong\u003eMounjaro\u003c\/strong\u003e, \u003cstrong\u003eZepbound\u003c\/strong\u003e, \u003cstrong\u003eKisunla\u003c\/strong\u003e, and \u003cstrong\u003eVerzenio\u003c\/strong\u003e support its market position. You’ll see how the company reaches patients through \u003cstrong\u003eU.S. and global commercialization\u003c\/strong\u003e, specialty pharmacies, health systems, \u003cstrong\u003eLillyDirect\u003c\/strong\u003e, retail and mail-order channels, and how it uses heavy HCP promotion, direct-to-consumer obesity advertising, conference data launches, and premium specialty-drug pricing with rebates, copay support, and cash-pay options.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eEli Lilly and Company - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company’s product mix centers on \u003cstrong\u003etirzepatide\u003c\/strong\u003e, \u003cstrong\u003edonanemab\u003c\/strong\u003e, and \u003cstrong\u003eabemaciclib\u003c\/strong\u003e. In \u003cstrong\u003e2023\u003c\/strong\u003e, Mounjaro and Verzenio each generated \u003cstrong\u003e$5.1 billion\u003c\/strong\u003e in revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eActive ingredient\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eMain use\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eKey numbers\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMounjaro\u003c\/td\u003e\n    \u003ctd\u003etirzepatide\u003c\/td\u003e\n    \u003ctd\u003eonce-weekly subcutaneous injection; \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003etype 2 diabetes\u003c\/td\u003e\n    \u003ctd\u003eSURPASS-2: \u003cstrong\u003e40 weeks\u003c\/strong\u003e; HbA1c change of \u003cstrong\u003e2.01%\u003c\/strong\u003e, \u003cstrong\u003e2.24%\u003c\/strong\u003e, \u003cstrong\u003e2.30%\u003c\/strong\u003e; weight change of \u003cstrong\u003e7.6 kg\u003c\/strong\u003e, \u003cstrong\u003e9.3 kg\u003c\/strong\u003e, \u003cstrong\u003e11.2 kg\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eZepbound\u003c\/td\u003e\n    \u003ctd\u003etirzepatide\u003c\/td\u003e\n    \u003ctd\u003eonce-weekly subcutaneous injection; \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003echronic weight management; BMI of \u003cstrong\u003e30\u003c\/strong\u003e or more, or \u003cstrong\u003e27\u003c\/strong\u003e or more with at least 1 weight-related condition\u003c\/td\u003e\n    \u003ctd\u003eSURMOUNT-1: \u003cstrong\u003e72 weeks\u003c\/strong\u003e; mean weight loss of \u003cstrong\u003e15.0%\u003c\/strong\u003e, \u003cstrong\u003e19.5%\u003c\/strong\u003e, \u003cstrong\u003e20.9%\u003c\/strong\u003e; placebo \u003cstrong\u003e3.1%\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eKisunla\u003c\/td\u003e\n    \u003ctd\u003edonanemab\u003c\/td\u003e\n    \u003ctd\u003eonce-monthly intravenous infusion\u003c\/td\u003e\n    \u003ctd\u003eearly symptomatic Alzheimer’s disease\u003c\/td\u003e\n    \u003ctd\u003eTRAILBLAZER-ALZ 2: \u003cstrong\u003e1,736\u003c\/strong\u003e participants; \u003cstrong\u003e76 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVerzenio\u003c\/td\u003e\n    \u003ctd\u003eabemaciclib\u003c\/td\u003e\n    \u003ctd\u003eoral tablet; twice daily\u003c\/td\u003e\n    \u003ctd\u003eHR-positive, HER2-negative breast cancer\u003c\/td\u003e\n    \u003ctd\u003e2023 revenue \u003cstrong\u003e$5.1 billion\u003c\/strong\u003e; monarchE: \u003cstrong\u003e5,637\u003c\/strong\u003e patients\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGLP-1 pipeline\u003c\/td\u003e\n    \u003ctd\u003etirzepatide extensions; oral GLP-1 programs such as orforglipron\u003c\/td\u003e\n    \u003ctd\u003einjectable and oral\u003c\/td\u003e\n    \u003ctd\u003ediabetes, obesity, sleep apnea, and other cardiometabolic uses\u003c\/td\u003e\n    \u003ctd\u003eSURMOUNT-OSA: \u003cstrong\u003e469\u003c\/strong\u003e adults across \u003cstrong\u003e2\u003c\/strong\u003e phase 3 trials\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMounjaro\u003c\/strong\u003e is the diabetes anchor in Eli Lilly and Company’s product mix. The product uses tirzepatide, a dual GIP\/GLP-1 receptor agonist, and is sold as a once-weekly injection across \u003cstrong\u003e6\u003c\/strong\u003e strengths: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e. In SURPASS-2, after \u003cstrong\u003e40 weeks\u003c\/strong\u003e, HbA1c changed by \u003cstrong\u003e2.01%\u003c\/strong\u003e at \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e2.24%\u003c\/strong\u003e at \u003cstrong\u003e10 mg\u003c\/strong\u003e, and \u003cstrong\u003e2.30%\u003c\/strong\u003e at \u003cstrong\u003e15 mg\u003c\/strong\u003e, versus \u003cstrong\u003e1.86%\u003c\/strong\u003e with semaglutide \u003cstrong\u003e1 mg\u003c\/strong\u003e. Body weight changed by \u003cstrong\u003e7.6 kg\u003c\/strong\u003e, \u003cstrong\u003e9.3 kg\u003c\/strong\u003e, and \u003cstrong\u003e11.2 kg\u003c\/strong\u003e, versus \u003cstrong\u003e5.7 kg\u003c\/strong\u003e with semaglutide.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eZepbound\u003c\/strong\u003e is the obesity product built on the same tirzepatide platform. It is marketed for adults with BMI of \u003cstrong\u003e30\u003c\/strong\u003e or more, or \u003cstrong\u003e27\u003c\/strong\u003e or more with at least \u003cstrong\u003e1\u003c\/strong\u003e weight-related condition. In SURMOUNT-1, mean weight loss at \u003cstrong\u003e72 weeks\u003c\/strong\u003e was \u003cstrong\u003e15.0%\u003c\/strong\u003e with \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e19.5%\u003c\/strong\u003e with \u003cstrong\u003e10 mg\u003c\/strong\u003e, and \u003cstrong\u003e20.9%\u003c\/strong\u003e with \u003cstrong\u003e15 mg\u003c\/strong\u003e, compared with \u003cstrong\u003e3.1%\u003c\/strong\u003e for placebo. The same molecule also extends into sleep apnea development, where SURMOUNT-OSA enrolled \u003cstrong\u003e469\u003c\/strong\u003e adults across \u003cstrong\u003e2\u003c\/strong\u003e phase 3 trials.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKisunla\u003c\/strong\u003e is donanemab, an anti-amyloid monoclonal antibody for early symptomatic Alzheimer’s disease. The pivotal TRAILBLAZER-ALZ 2 study enrolled \u003cstrong\u003e1,736\u003c\/strong\u003e participants and followed them for \u003cstrong\u003e76 weeks\u003c\/strong\u003e. That makes Kisunla a biologic product with a very different delivery model from the company’s weekly injectable metabolic products and oral oncology therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVerzenio\u003c\/strong\u003e is abemaciclib, an oral CDK4\/6 inhibitor used in HR-positive, HER2-negative breast cancer. Eli Lilly and Company reported \u003cstrong\u003e$5.1 billion\u003c\/strong\u003e of Verzenio revenue in \u003cstrong\u003e2023\u003c\/strong\u003e, and the monarchE study enrolled \u003cstrong\u003e5,637\u003c\/strong\u003e patients. The product matters because it gives the company a durable oncology franchise with an oral, twice-daily dosage form rather than an injectable format.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e marketed tirzepatide brands: Mounjaro and Zepbound\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e dose strengths for each tirzepatide brand: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e to \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e72 weeks\u003c\/strong\u003e of pivotal weight-loss data for Zepbound in SURMOUNT-1\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e40 weeks\u003c\/strong\u003e of pivotal diabetes data for Mounjaro in SURPASS-2\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1,736\u003c\/strong\u003e participants in the Kisunla pivotal study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5,637\u003c\/strong\u003e patients in the Verzenio monarchE study\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eEli Lilly and Company - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e: LillyDirect launched in \u003cstrong\u003e50\u003c\/strong\u003e states and Washington, D.C.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e: manufacturing expansion announced for Lebanon, Indiana.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.2 million square feet\u003c\/strong\u003e: planned size of the Lebanon, Indiana manufacturing site.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eU.S. and global commercialization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e states\u003c\/li\u003e\n  \u003cli\u003eWashington, D.C.\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty pharmacies and health systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003eSpecialty pharmacies\u003c\/li\u003e\n  \u003cli\u003eHealth systems\u003c\/li\u003e\n  \u003cli\u003eLimited-distribution medicines\u003c\/li\u003e\n  \u003cli\u003eClinic-based administration\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLillyDirect direct-to-consumer access\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e states\u003c\/li\u003e\n  \u003cli\u003eWashington, D.C.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetail and mail-order fulfillment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003eRetail pharmacies\u003c\/li\u003e\n  \u003cli\u003eMail-order pharmacies\u003c\/li\u003e\n  \u003cli\u003eDirect shipment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpanding manufacturing footprint\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e1.2 million square feet\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003eLebanon, Indiana\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePlace channel\u003c\/td\u003e\n    \u003ctd\u003eNumber\u003c\/td\u003e\n    \u003ctd\u003eLocation\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLillyDirect\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e states and Washington, D.C.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing expansion\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLebanon, Indiana\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing site size\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1.2 million square feet\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLebanon, Indiana\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGeographic access\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eStates\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFederal district access\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eWashington, D.C.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eEli Lilly and Company - Marketing Mix: Promotion\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e2023-11-08\u003c\/strong\u003e, \u003cstrong\u003e2024\u003c\/strong\u003e, \u003cstrong\u003e2,539\u003c\/strong\u003e, \u003cstrong\u003e1,879\u003c\/strong\u003e, \u003cstrong\u003e72\u003c\/strong\u003e, \u003cstrong\u003e40\u003c\/strong\u003e, \u003cstrong\u003e15.0%\u003c\/strong\u003e, \u003cstrong\u003e19.5%\u003c\/strong\u003e, \u003cstrong\u003e20.9%\u003c\/strong\u003e, \u003cstrong\u003e2.01\u003c\/strong\u003e, \u003cstrong\u003e2.24\u003c\/strong\u003e, \u003cstrong\u003e2.30\u003c\/strong\u003e, \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e, \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHeavy HCP field promotion is built on \u003cstrong\u003e2,539\u003c\/strong\u003e-patient and \u003cstrong\u003e1,879\u003c\/strong\u003e-patient phase 3 datasets, with \u003cstrong\u003e72\u003c\/strong\u003e-week and \u003cstrong\u003e40\u003c\/strong\u003e-week endpoints, and dose levels from \u003cstrong\u003e2.5 mg\u003c\/strong\u003e to \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eDirect-to-consumer obesity advertising is anchored to \u003cstrong\u003e2023-11-08\u003c\/strong\u003e, when Zepbound received U.S. approval, and to the dose ladder of \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e. The clinical proof points used in that message include \u003cstrong\u003e15.0%\u003c\/strong\u003e, \u003cstrong\u003e19.5%\u003c\/strong\u003e, and \u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss, versus \u003cstrong\u003e3.1%\u003c\/strong\u003e for placebo.\u003c\/p\u003e\n\n\u003cp\u003eLillyDirect launched in \u003cstrong\u003e2024\u003c\/strong\u003e, with self-pay vial prices of \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eConference-driven clinical data launches use exact sample sizes and endpoints: SURMOUNT-1 at \u003cstrong\u003e2,539\u003c\/strong\u003e adults over \u003cstrong\u003e72\u003c\/strong\u003e weeks, and SURPASS-2 at \u003cstrong\u003e1,879\u003c\/strong\u003e adults over \u003cstrong\u003e40\u003c\/strong\u003e weeks. The promotion package also uses HbA1c reductions of \u003cstrong\u003e2.01\u003c\/strong\u003e, \u003cstrong\u003e2.24\u003c\/strong\u003e, and \u003cstrong\u003e2.30\u003c\/strong\u003e percentage points.\u003c\/p\u003e\n\n\u003cp\u003eDisease-awareness and support programs sit on the same numeric story: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e starter dosing, \u003cstrong\u003e15 mg\u003c\/strong\u003e ceiling dosing, and \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e cash-pay access points.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromotion area\u003c\/td\u003e\n\u003ctd\u003eReal-life number or amount\u003c\/td\u003e\n\u003ctd\u003eReal-life promotional anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeavy HCP field promotion\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e; \u003cstrong\u003e72\u003c\/strong\u003e; \u003cstrong\u003e15.0%\u003c\/strong\u003e; \u003cstrong\u003e19.5%\u003c\/strong\u003e; \u003cstrong\u003e20.9%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSURMOUNT-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeavy HCP field promotion\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,879\u003c\/strong\u003e; \u003cstrong\u003e40\u003c\/strong\u003e; \u003cstrong\u003e2.01\u003c\/strong\u003e; \u003cstrong\u003e2.24\u003c\/strong\u003e; \u003cstrong\u003e2.30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSURPASS-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect-to-consumer obesity advertising\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2023-11-08\u003c\/strong\u003e; \u003cstrong\u003e2.5 mg\u003c\/strong\u003e; \u003cstrong\u003e5 mg\u003c\/strong\u003e; \u003cstrong\u003e7.5 mg\u003c\/strong\u003e; \u003cstrong\u003e10 mg\u003c\/strong\u003e; \u003cstrong\u003e12.5 mg\u003c\/strong\u003e; \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eZepbound approval and dose ladder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLillyDirect patient engagement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e$399\u003c\/strong\u003e; \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDigital access and self-pay pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConference-driven clinical data launches\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e; \u003cstrong\u003e1,879\u003c\/strong\u003e; \u003cstrong\u003e72\u003c\/strong\u003e; \u003cstrong\u003e40\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMeeting-stage clinical evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease-awareness and support programs\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.5 mg\u003c\/strong\u003e; \u003cstrong\u003e15 mg\u003c\/strong\u003e; \u003cstrong\u003e$399\u003c\/strong\u003e; \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAccess and support pathway\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e2023-11-08\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2,539\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e1,879\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e72\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e15.0%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e20.9%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2.01\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2.30\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$399\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$549\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eEli Lilly and Company - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePremium specialty-drug pricing:\u003c\/strong\u003e Zepbound list price: \u003cstrong\u003e$1,059.87\u003c\/strong\u003e per month. LillyDirect self-pay vial prices: \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e. Difference from list price: \u003cstrong\u003e$660.87\u003c\/strong\u003e and \u003cstrong\u003e$510.87\u003c\/strong\u003e. Price reduction versus list: \u003cstrong\u003e62.4%\u003c\/strong\u003e and \u003cstrong\u003e48.2%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNet pricing shaped by rebates:\u003c\/strong\u003e Eli Lilly and Company cut U.S. insulin list prices by \u003cstrong\u003e70%\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e. Humalog and Humulin insulin access under the Lilly Insulin Value Program: \u003cstrong\u003e$35\u003c\/strong\u003e per month.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCopay support for patients:\u003c\/strong\u003e \u003cstrong\u003e$35\u003c\/strong\u003e per month for Lilly insulins under the Lilly Insulin Value Program. Eli Lilly and Company patient support programs for selected medicines have used \u003cstrong\u003e$25\u003c\/strong\u003e as a copay floor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCash-pay access options:\u003c\/strong\u003e LillyDirect self-pay access points: \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e. Against a \u003cstrong\u003e$1,059.87\u003c\/strong\u003e list price, the cash-pay gap is \u003cstrong\u003e$660.87\u003c\/strong\u003e and \u003cstrong\u003e$510.87\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue-based access pressure:\u003c\/strong\u003e Medicare Part D out-of-pocket cap: \u003cstrong\u003e$2,000\u003c\/strong\u003e in \u003cstrong\u003e2025\u003c\/strong\u003e. Monthly specialty-drug pricing above \u003cstrong\u003e$1,000\u003c\/strong\u003e faces payer pressure under that ceiling.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePrice lever\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003ePrice point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound list price\u003c\/td\u003e\n\u003ctd\u003e$1,059.87\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eMonthly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound self-pay vial\u003c\/td\u003e\n\u003ctd\u003e$399\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eMonthly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound self-pay vial\u003c\/td\u003e\n\u003ctd\u003e$549\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eMonthly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin list-price cut\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin out-of-pocket cap\u003c\/td\u003e\n\u003ctd\u003e$35\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eMonthly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support copay floor\u003c\/td\u003e\n\u003ctd\u003e$25\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eSelected medicines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D out-of-pocket cap\u003c\/td\u003e\n\u003ctd\u003e$2,000\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eAnnual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$1,059.87\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$399\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$549\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$660.87\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$510.87\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e62.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e48.2%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$35\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$25\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$2,000\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602228965525,"sku":"lly-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/lly-marketing-mix.png?v=1740169491","url":"https:\/\/dcf-analysis.com\/products\/lly-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}